Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

NCT03509545 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class

Stopped recruitment issues

Conditions

Interventions

Sponsor

Sarfez Pharmaceuticals, Inc.